# JYP0322 (NCT06128148)

> Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06128148
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Guangzhou JOYO Pharma Co., Ltd
- Conditions: Protein Kinase Inhibitors; Other Protocol Specified Criteria; Lung Neoplasms; Brain Neoplasms
- Interventions: JYP0322 50 mg qd; JYP0322 100 mg qd; JYP0322 200 mg qd; JYP0322 100 mg bid; JYP0322 150 mg bid; JYP0322 200 mg bid; JYP0322 150mg tid
- Enrollment: 101
- Primary outcome: The frequency and severity of adverse events of JYP0322

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=jyp0322-nct06128148